Research in Focus

Journal article · Hepatology International · Published 3 July 2026

Two decades of MASLD in Taiwan: large-cohort data highlight priorities for early prevention

Data from 426,478 adults reveal the disease burden and metabolic risks across age groups. Signals of an increase among younger adults highlight the need to connect health assessment with follow-up care earlier.

426,478Adults in the study sample from two cohorts
35.1%Overall MASLD prevalence in the study sample
2001–2021Period covered by the study data

These figures describe the study sample and are not representative estimates for Taiwan’s entire population.

01 / Research Question

How large is the disease burden, and which groups warrant priority attention?

Metabolic dysfunction-associated steatotic liver disease (MASLD) involves more than the liver: it is closely linked to body weight, waist circumference, blood glucose, and other metabolic conditions. This collaborative, multi-institutional study, involving researchers from Kaohsiung Medical University and its affiliated hospital, used data accumulated over many years to describe disease distribution and changes across population groups.

The study’s value lies in addressing both the size of the burden and the metabolic factors that warrant earlier attention. It provides local evidence for disease surveillance, risk stratification, and future intervention research.

02 / Data and Methods

Combining two large cohorts to understand disease distribution in the sample

The study included 426,478 adults from the Taiwan Biobank and the MJ health screening database. It compared cross-sectional data from different periods, measuring the proportion of participants meeting the disease definition in each period, rather than following individuals to measure the incidence of new disease.

MASLD requires fat accumulation in the liver together with at least one cardiometabolic risk factor. The study assessed five domains: body weight or waist circumference, blood glucose, blood pressure, triglycerides, and high-density lipoprotein cholesterol. Fatty liver was determined using ultrasound or surrogate indices.

Two distinctions to keep in mind

Prevalence is not the same as incidence, and risk related to body weight or waist circumference should not be labeled simply as “obesity prevalence.” The definitions and sample composition used in the study affect how the figures should be interpreted.

03 / Main Findings

The overall proportion increased; age-specific analyses clarify the pattern

Overall MASLD prevalence in the study sample was 35.1%. Comparing the first and last periods, crude prevalence increased from 31.1% in 2001–2005 to 37.9% in 2016–2021: a difference of 6.8 percentage points, or a relative increase of 21.9%. These two measures have different meanings and are not interchangeable.

However, the composition of the pooled data by source changed over time, and the adjusted overall age-period-cohort model did not show a statistically significant overall period trend. Differences in crude proportions alone therefore cannot establish that disease increased continuously at a uniform rate nationwide.

After 2010, signals of an increase were concentrated mainly among people under 40

Comparing 2001–2010 with 2011–2021, MASLD prevalence was higher in the later period among participants under 30 and those aged 30–39. The difference in the 40–49 age group was not statistically significant. The proportions in the pooled sample decreased among participants aged 50 and older, although their burden remained higher than that of younger groups.

Different ages, different patterns of change

MASLD prevalence in the study samples from two periods (%)

2001–20102011–2021

Under 30 years

2001–2010
15.1%
2011–2021
19.6%

30–39 years

2001–2010
30.0%
2011–2021
34.1%

40–49 years

2001–2010
41.3%
2011–2021
40.8%

50–59 years

2001–2010
51.7%
2011–2021
42.5%

60 years and older

2001–2010
53.8%
2011–2021
43.2%
All bars start at 0%, and both periods use the same scale. The difference between periods for the 40–49 age group was not statistically significant (p=0.186). Values are from Table 2 of the original article, with age-group boundaries harmonized according to Table 1. All values are proportions in the study sample, not estimates for the entire population.

When the analysis was restricted to MJ data, the study still observed a more pronounced signal of an increase among younger adults. This supports giving attention to younger groups, but the decreases among older groups in the pooled sample cannot be interpreted as proof of successful prevention or a reduction in disease among older people nationwide.

Body weight and blood glucose are priority metabolic factors

Risk related to body weight or waist circumference, and prediabetes or diabetes, were the two most common cardiometabolic risk factors in the study. Changes in body weight and waist circumference among younger groups, and the burden of dysglycemia among older groups, suggest that prevention strategies should be tailored to each population’s needs rather than guided by a single overall average.

04 / Study Limitations

Recognizing trends while respecting the limits of interpretation

  • This was not a nationwide random sample. Participants in the two cohorts do not represent all residents of Taiwan, and regional differences cannot be directly generalized.
  • The composition of the data sources changes. Age, sex, and the proportions contributed by each database differed across periods. Comparisons of crude prevalence need to be considered alongside stratified and adjusted analyses.
  • Some fatty liver assessments relied on surrogate indices. Different measurement methods may affect disease classification and the resulting proportions.
  • Association does not establish causation. This study did not test the effects of interventions or demonstrate reductions in mortality, fibrosis, or healthcare costs.

05 / From Evidence to Action

Linking assessment with care earlier, while building intervention evidence

These observations suggest giving priority to ways of connecting body-weight, waist-circumference, and blood-glucose assessments in health screening, community settings, and primary care with ongoing follow-up and appropriate health support. Both early prevention for young adults and metabolic care for middle-aged and older groups warrant inclusion.

These are directions for prevention and care informed by the findings, rather than intervention benefits demonstrated by this study. The next step is to design and evaluate interventions for different populations, assessing their effectiveness through disease progression, long-term health outcomes, and resource use.

For general readers

This article provides research information, not individual diagnostic or treatment advice. Discuss personal risks and testing needs with a qualified healthcare professional.

Original Article

Yeh ML, Tsai PC, Huang CF, et al. Prevalence and associated factors of metabolic dysfunction-associated steatotic liver disease in Taiwan, 2001–2021. Hepatology International. Published online 3 July 2026.

View the journal abstract and full article

DOI: 10.1007/s12072-026-11123-2
Website research summary and chart: this page was prepared from the original research data. The original article’s authors are listed above.

Quarterly report further reading | Editorial update: 22 October 2026

The extended quarterly draft, “Disease Burden and Metabolic Risk in MASLD in Taiwan: Implications for Early Prevention and Management”, was written by Edward Hsi, PhD / Ming-Lun Yeh, MD PhD and dated 6 October 2026. The filename does not establish the publication issue. This page continues to use the formal paper published on 3 July 2026; no duplicate research article has been created.

The draft discusses the higher burden in men and larger relative increases in selected metabolic risks in women. Regional findings remain sensitive to sample composition and data sources. These observations can inform further research by age and population group; they do not establish benefits from a specific care intervention. Prototype testing, initial implementation and wider rollout are different stages. The draft’s September 2026 implementation statement and three-year expansion target describe progress and plans at that time, rather than nationwide delivery achieved by this editorial update.

Historical research communication and data-version note | 中文版

Images: no journal figures supplied with the quarterly draft were newly uploaded or reproduced in this update. Existing website charts remain; see the original-paper link above.

Go to top